#1 Clinical Trials Search in Europe

Bbp-398

BBP-398, formerly known as IACS-15509, is a potent, selective, orally active allosteric inhibitor of SHP2, a tyrosine phosphatase that plays a key role in the RTK-MAPK signal transduction pathway. This article explores the ongoing clinical trials investigating BBP-398 as a potential treatment for various advanced solid tumors, including non-small cell lung cancer (NSCLC) with specific genetic mutations. These trials aim to evaluate the safety, efficacy, and optimal dosing of BBP-398 alone and in combination with other targeted therapies.

Table of Contents

What is BBP-398?

BBP-398, also known as IACS-15509, is a new drug being studied for the treatment of various types of cancer[1][2]. It is taken orally as a capsule and is currently being tested in clinical trials to determine its safety and effectiveness[3].

How Does BBP-398 Work?

BBP-398 is a type of drug called a SHP2 inhibitor. SHP2 is a protein in our cells that plays an important role in cell growth and survival. In some cancers, SHP2 can become overactive, leading to uncontrolled cell growth. BBP-398 works by blocking the activity of SHP2, which may help slow down or stop the growth of cancer cells[1].

Specifically, BBP-398 affects a communication pathway in cells called the RTK-MAPK pathway. This pathway is like a chain of messengers that tells cells when to grow and divide. In many cancers, this pathway is too active. By inhibiting SHP2, BBP-398 aims to disrupt this overactive signaling and potentially slow down cancer growth[2].

What Conditions Does BBP-398 Treat?

BBP-398 is being studied for the treatment of several types of cancer, including:

  • Advanced solid tumors: These are cancers that form solid masses in the body and have spread or become difficult to treat with standard therapies[1].
  • Non-small cell lung cancer (NSCLC): This is the most common type of lung cancer. BBP-398 is being studied particularly in NSCLC patients with specific genetic mutations, such as KRAS or EGFR mutations[2][4].
  • Metastatic cancers: These are cancers that have spread from their original location to other parts of the body[5].

Clinical Trials and Research

BBP-398 is currently being studied in several clinical trials to determine its safety, the right dose to use, and how well it works against different types of cancer. These trials are typically divided into phases:

  • Phase 1 trials: These are the first tests in humans, focusing on safety and finding the right dose[3].
  • Phase 1a/1b trials: These trials continue to study safety but also start to look at how well the drug works against cancer[5].

Researchers are measuring several outcomes in these trials, including:

  • Safety and side effects: They’re closely monitoring any adverse events that patients experience[5].
  • How the body processes the drug (pharmacokinetics): This includes how quickly the drug reaches its maximum concentration in the blood, how long it stays in the body, and how it’s eliminated[1].
  • How well the drug works against cancer: This includes measuring if tumors shrink or disappear (response rate) and how long the benefits last[4].

Combination Therapies

BBP-398 is also being studied in combination with other cancer drugs. This approach aims to enhance the effectiveness of treatment. Some combinations being studied include:

  • BBP-398 with sotorasib: This combination is being tested in patients with KRAS G12C mutated cancers[5].
  • BBP-398 with osimertinib: This combination is being studied in lung cancer patients with EGFR mutations[2].
  • BBP-398 with nivolumab: This combination is being tested in lung cancer patients with KRAS mutations[4].

Side Effects and Safety

As BBP-398 is still in clinical trials, all of its potential side effects are not yet known. The ongoing studies are carefully monitoring patients for any adverse events. Some things being closely watched include:

  • Changes in blood tests
  • Effects on vital signs
  • Changes in heart rhythm (measured by ECG)
  • Any other unexpected side effects[5]

It’s important to note that as a participant in a clinical trial, patients are closely monitored by healthcare professionals. Any side effects are promptly addressed and may lead to adjustments in treatment or additional care as needed.

Trial Phase Study Focus Combination Therapy Primary Outcomes
Phase I Advanced solid tumors BBP-398 monotherapy Safety, tolerability, MTD, RP2D
Phase I Advanced solid tumors with KRAS-G12C mutation BBP-398 + Sotorasib Safety, tolerability, RP2D, ORR
Phase Ia/Ib NSCLC with EGFR mutations BBP-398 + Osimertinib Safety, tolerability, ORR
Phase I NSCLC with KRAS mutation BBP-398 + Nivolumab Safety, tolerability, RP2D, ORR

FAQ

  • What is BBP-398 and how does it work? BBP-398 is a potent, selective, orally active allosteric inhibitor of SHP2, a tyrosine phosphatase involved in the RTK-MAPK signal transduction pathway. It works by inhibiting SHP2, which plays a role in activating the downstream MAPK signaling pathway, potentially slowing down or stopping the growth of certain cancer cells.
  • What types of cancer are being studied with BBP-398? BBP-398 is being studied in clinical trials for various advanced solid tumors, with a particular focus on non-small cell lung cancer (NSCLC) with specific genetic mutations such as KRAS and EGFR mutations. Other solid tumors with MAPK pathway or RTK-driven characteristics are also being investigated.
  • Is BBP-398 being studied alone or in combination with other drugs? BBP-398 is being studied both as a monotherapy and in combination with other drugs. Combination studies include BBP-398 with sotorasib (a KRAS-G12C inhibitor), osimertinib (an EGFR inhibitor), and nivolumab (a PD-1 antibody).
  • What are the main goals of the BBP-398 clinical trials? The main goals of the BBP-398 clinical trials are to evaluate its safety, tolerability, and efficacy in treating advanced solid tumors. Researchers are also determining the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and assessing pharmacokinetics, pharmacodynamics, and potential biomarkers of response.
  • How is the effectiveness of BBP-398 being measured in these trials? The effectiveness of BBP-398 is primarily being measured by objective response rate (ORR), which includes complete and partial responses to treatment. Other measures include duration of response (DOR), progression-free survival (PFS), and overall survival (OS) in some studies.

Ongoing Clinical Trials on Bbp-398

  • Study of BMS-986466 with Adagrasib and Cetuximab for Patients with KRAS G12C-mutant Advanced Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Finland France Italy Spain

Glossary

  • SHP2: A tyrosine phosphatase that plays a key role in the RTK-MAPK signal transduction pathway, involved in cell growth and survival.
  • MAPK pathway: A chain of proteins in the cell that communicates a signal from a receptor on the surface of the cell to the DNA in the nucleus, involved in cell division and growth.
  • NSCLC: Non-small cell lung cancer, a type of lung cancer that is the most common form of the disease.
  • KRAS mutation: A genetic alteration in the KRAS gene, which is often found in certain types of cancer and can affect treatment response.
  • EGFR mutation: A genetic alteration in the epidermal growth factor receptor (EGFR) gene, commonly found in some lung cancers and influencing treatment decisions.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that does not cause unacceptable side effects.
  • Recommended Phase 2 Dose (RP2D): The dose of a drug recommended for further study in phase 2 clinical trials, based on safety and efficacy data from phase 1 trials.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body and the mechanisms of drug action.

References

  1. https://clinicaltrials.gov/study/NCT05621525
  2. https://clinicaltrials.gov/study/NCT06032936
  3. https://clinicaltrials.gov/study/NCT04528836
  4. https://clinicaltrials.gov/study/NCT05375084
  5. https://clinicaltrials.gov/study/NCT05480865